

Joakim Dillner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1719469/publications.pdf>

Version: 2024-02-01

329
papers

20,098
citations

15466

65
h-index

14156

128
g-index

338
all docs

338
docs citations

338
times ranked

13908
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>HPV</scp>â€Positive Status Is an Independent Factor Associated With Sinonasal Inverted Papilloma Recurrence. <i>Laryngoscope</i> , 2022, 132, 1714-1718.	1.1	3
2	Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115595.	0.8	28
3	Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil. <i>PLoS ONE</i> , 2022, 17, e0262724.	1.1	5
4	Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1522-1528.	0.8	20
5	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	5.8	21
6	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. <i>Clinical and Translational Immunology</i> , 2022, 11, e1379.	1.7	4
7	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 813-820.	4.6	64
8	Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden. <i>JAMA Network Open</i> , 2022, 5, e228109.	2.8	12
9	Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses. <i>Journal of Infectious Diseases</i> , 2022, 226, 1195-1199.	1.9	3
10	Human papillomavirus selfâ€sampling with <scp>mRNA</scp> testing benefits routine screening. <i>International Journal of Cancer</i> , 2022, 151, 1989-1996.	2.3	3
11	Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. <i>Journal of Clinical Virology</i> , 2022, 154, 105237.	1.6	10
12	Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2995-e3001.	2.9	75
13	Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs. <i>American Journal of Epidemiology</i> , 2021, 190, 506-514.	1.6	18
14	Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 972-981.	1.4	17
15	Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort. <i>Journal of Infectious Diseases</i> , 2021, 223, 1992-2000.	1.9	14
16	Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. <i>Clinical Infectious Diseases</i> , 2021, 72, e890-e892.	2.9	5
17	How Many Human Papillomavirus Types Do We Need to Screen For?. <i>Journal of Infectious Diseases</i> , 2021, 223, 1510-1511.	1.9	19
18	Systematic evaluation of SARSâ€CoVâ€2 antigens enables a highly specific and sensitive multiplex serological COVIDâ€19 assay. <i>Clinical and Translational Immunology</i> , 2021, 10, e1312.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries. <i>Journal of Medical Screening</i> , 2021, 28, 464-471.	1.1	2
20	Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer. <i>International Journal of Cancer</i> , 2021, 149, 684-691.	2.3	7
21	A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 101, 106266.	0.8	14
22	Validation of the cobas 6800 human papillomavirus test in primary cervical screening. <i>PLoS ONE</i> , 2021, 16, e0247291.	1.1	3
23	High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers. <i>Journal of Infectious Diseases</i> , 2021, 224, 14-20.	1.9	8
24	Elimination of HPV-associated oropharyngeal cancers in Nordic countries. <i>Preventive Medicine</i> , 2021, 144, 106445.	1.6	9
25	Antibodies to SARS-CoV-2 and risk of past or future sick leave. <i>Scientific Reports</i> , 2021, 11, 5160.	1.6	8
26	SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden. <i>Journal of Internal Medicine</i> , 2021, 290, 430-436.	2.7	4
27	Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women. <i>Microorganisms</i> , 2021, 9, 750.	1.6	10
28	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. <i>Scientific Reports</i> , 2021, 11, 7614.	1.6	26
29	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. <i>American Journal of Preventive Medicine</i> , 2021, 60, 478-487.	1.6	13
30	Transcription of human papillomaviruses in nonmelanoma skin cancers of the immunosuppressed. <i>International Journal of Cancer</i> , 2021, 149, 1341-1347.	2.3	7
31	Misclassifications in human papillomavirus databases. <i>Virology</i> , 2021, 558, 57-66.	1.1	9
32	Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003588.	3.9	8
33	Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. <i>Scandinavian Journal of Public Health</i> , 2021, 49, 707-712.	1.2	10
34	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3695.	5.8	32
35	Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment. <i>Aids</i> , 2021, 35, 2367-2374.	1.0	3
36	Decoding our environment: The European Human Exposome Network. <i>ISEE Conference Abstracts</i> , 2021, .	0.0	0

#	ARTICLE	IF	CITATIONS
37	Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial. <i>PLoS Medicine</i> , 2021, 18, e1003748.	3.9	9
38	Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program. <i>International Journal of Cancer</i> , 2021, 149, 2083-2090.	2.3	4
39	The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. <i>Journal of Clinical Virology</i> , 2021, 141, 104902.	1.6	18
40	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
41	Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic. <i>PLoS ONE</i> , 2021, 16, e0257854.	1.1	5
42	Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827.	1.6	9
43	Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics. <i>Scientific Reports</i> , 2021, 11, 18852.	1.6	9
44	Severe features during outbreak but low mortality observed immediately before and after a March–May 2020 COVID-19 outbreak in Stockholm, Sweden. <i>International Journal of Infectious Diseases</i> , 2021, 110, 433-435.	1.5	2
45	Differences in risk for SARS-CoV-2 infection among healthcare workers. <i>Preventive Medicine Reports</i> , 2021, 24, 101518.	0.8	17
46	Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer. <i>Acta Cytologica</i> , 2021, 65, 377-384.	0.7	6
47	Human exposome assessment platform. <i>Environmental Epidemiology</i> , 2021, 5, e182.	1.4	7
48	Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0260453.	1.1	3
49	Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. <i>BMJ Open</i> , 2021, 11, e050669.	0.8	16
50	Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. <i>BMJ Open</i> , 2021, 11, e048337.	0.8	2
51	WITHDRAWAL—Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. <i>Tumori</i> , 2020, 106, NP2-NP4.	0.6	1
52	Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program. <i>International Journal of Cancer</i> , 2020, 146, 1230-1240.	2.3	32
53	Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 253.e1-253.e8.	0.7	19
54	Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2582-2590.	2.9	45

#	ARTICLE	IF	CITATIONS
55	Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study. <i>International Journal of Cancer</i> , 2020, 146, 2539-2546.	2.3	15
56	Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	2.3	8
57	Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. <i>British Journal of Cancer</i> , 2020, 123, 1790-1795.	2.9	36
58	HPV Vaccination and the Risk of Invasive Cervical Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1340-1348.	13.9	723
59	Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. <i>Vaccine</i> , 2020, 38, 4066-4070.	1.7	12
60	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. <i>PLoS ONE</i> , 2020, 15, e0236394.	1.1	8
61	Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. <i>EClinicalMedicine</i> , 2020, 23, 100401.	3.2	86
62	Authors' reply. <i>Vaccine</i> , 2020, 38, 5741.	1.7	0
63	De novo sequence assembly requires bioinformatic checking of chimeric sequences. <i>PLoS ONE</i> , 2020, 15, e0237455.	1.1	18
64	Impact of HPV vaccination on cervical screening performance: a population-based cohort study. <i>British Journal of Cancer</i> , 2020, 123, 155-160.	2.9	40
65	Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study. <i>Acta Oncologica</i> , 2020, 59, 988-993.	0.8	10
66	Clinical validation of full genotyping CLART [®] HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. <i>BMC Cancer</i> , 2020, 20, 396.	1.1	9
67	Human Papillomavirus Seroprevalence and Seroconversion Among Men Living With HIV: Cohort Study in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 141-148.	0.9	2
68	Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage. <i>International Journal of Cancer</i> , 2020, 147, 3511-3522.	2.3	13
69	Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2020, 10, 9070.	1.6	14
70	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). <i>British Journal of Cancer</i> , 2020, 123, 510-517.	2.9	74
71	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. <i>Journal of Infectious Diseases</i> , 2020, 222, 948-956.	1.9	29
72	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. <i>International Journal of Cancer</i> , 2020, 147, 1855-1863.	2.3	6

#	ARTICLE	IF	CITATIONS
73	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. <i>International Journal of Cancer</i> , 2020, 147, 9-13.	2.3	6
74	Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. <i>Journal of General Virology</i> , 2020, 101, 265-270.	1.3	16
75	HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2662-2668.	1.1	9
76	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
77	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
78	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
79	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
80	HPV mRNA and HPV DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. <i>International Journal of Cancer</i> , 2019, 144, 1073-1081.	2.3	22
81	The HPV16 Genome Is Stable in Women Who Progress to <i>In Situ</i> or Invasive Cervical Cancer: A Prospective Population-Based Study. <i>Cancer Research</i> , 2019, 79, 4532-4538.	0.4	8
82	Author's reply to: Human papillomavirus type 197 is not associated with skin tumors. <i>International Journal of Cancer</i> , 2019, 145, 3181-3181.	2.3	1
83	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. <i>PLoS ONE</i> , 2019, 14, e0222271.	1.1	84
84	The Launch of an International Animal Papillomavirus Reference Center. <i>Viruses</i> , 2019, 11, 55.	1.5	10
85	Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	2.0	41
86	Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ study. <i>BMC Cancer</i> , 2019, 19, 111.	1.1	13
87	Cancer Prevention Europe. <i>Molecular Oncology</i> , 2019, 13, 528-534.	2.1	70
88	Early detection and prevention. <i>Molecular Oncology</i> , 2019, 13, 591-598.	2.1	6
89	Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women – Potential for prevention. <i>Cancer Medicine</i> , 2019, 8, 839-849.	1.3	13
90	NordScreen – an interactive tool for presenting cervical cancer screening indicators in the Nordic countries. <i>Acta Oncologica</i> , 2019, 58, 1199-1204.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. <i>Gynecologic Oncology</i> , 2019, 154, 354-359.	0.6	36
92	HPV transcription in skin tumors. <i>PLoS ONE</i> , 2019, 14, e0217942.	1.1	10
93	Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. <i>International Journal of Cancer</i> , 2019, 145, 3033-3039.	2.3	32
94	A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin. <i>BMC Cancer</i> , 2019, 19, 265.	1.1	17
95	Roadmap for a precision-medicine initiative in the Nordic region. <i>Nature Genetics</i> , 2019, 51, 924-930.	9.4	22
96	Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1207.	2.4	18
97	Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). <i>International Journal of Cancer</i> , 2019, 145, 785-796.	2.3	20
98	Some clear answers regarding transmission of genital human papillomavirus. <i>Lancet Infectious Diseases</i> , 2019, 19, 227-228.	4.6	0
99	Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. <i>Journal of Infectious Diseases</i> , 2019, 219, 582-589.	1.9	30
100	Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs. <i>Journal of Infectious Diseases</i> , 2019, 219, 489-496.	1.9	2
101	Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. <i>European Journal of Cancer Prevention</i> , 2019, 28, 131-140.	0.6	16
102	Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study. <i>Journal of Clinical Oncology</i> , 2019, 37, 5525-5525.	0.8	1
103	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
104	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
105	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
106	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
107	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	12.5	129
108	Towards quality and order in human papillomavirus research. <i>Virology</i> , 2018, 519, 74-76.	1.1	54

#	ARTICLE	IF	CITATIONS
109	Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. <i>Journal of Clinical Virology</i> , 2018, 101, 74-85.	1.6	34
110	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. <i>Vaccine</i> , 2018, 36, 4792-4799.	1.7	60
111	Evaluation of HPV type replacement in unvaccinated and vaccinated adolescent females – Post-hoc analysis of a community-randomized clinical trial (II). <i>International Journal of Cancer</i> , 2018, 142, 2491-2500.	2.3	28
112	Vaccination protects against invasive HPV-associated cancers. <i>International Journal of Cancer</i> , 2018, 142, 2186-2187.	2.3	132
113	ViraPipe: scalable parallel pipeline for viral metagenome analysis from next generation sequencing reads. <i>Bioinformatics</i> , 2018, 34, 928-935.	1.8	14
114	Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. <i>Vaccine</i> , 2018, 36, 3239-3246.	1.7	6
115	Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 1377-1381.	2.9	43
116	Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure. <i>Journal of Infectious Diseases</i> , 2018, 218, 398-405.	1.9	13
117	Impact of gender-neutral or girls-only vaccination against human papillomavirus – Results of a community-randomized clinical trial (I). <i>International Journal of Cancer</i> , 2018, 142, 949-958.	2.3	42
118	A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. <i>Clinical Infectious Diseases</i> , 2018, 66, 339-345.	2.9	96
119	Status of implementation and organization of cancer screening in The European Union Member States – Summary results from the second European screening report. <i>International Journal of Cancer</i> , 2018, 142, 44-56.	2.3	169
120	High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders. <i>British Journal of Cancer</i> , 2018, 118, 138-144.	2.9	21
121	ICTV Virus Taxonomy Profile: Papillomaviridae. <i>Journal of General Virology</i> , 2018, 99, 989-990.	1.3	140
122	Cervical cancer screening in Sweden 2014-2016. <i>PLoS ONE</i> , 2018, 13, e0209003.	1.1	17
123	Machine Learning for detection of viral sequences in human metagenomic datasets. <i>BMC Bioinformatics</i> , 2018, 19, 336.	1.2	44
124	High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002666.	3.9	55
125	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. <i>Journal of Clinical Virology</i> , 2018, 108, 64-71.	1.6	37
126	Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study. <i>British Journal of Cancer</i> , 2018, 119, 1163-1168.	2.9	14

#	ARTICLE	IF	CITATIONS
127	Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. <i>Aids</i> , 2018, 32, 1475-1484.	1.0	8
128	Determinants of the presence of human papillomaviruses in the anal canal of Russian men. <i>Journal of Medical Virology</i> , 2018, 90, 1643-1650.	2.5	6
129	Viremia preceding multiple sclerosis: Two nested case-control studies. <i>Virology</i> , 2018, 520, 21-29.	1.1	3
130	Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). <i>International Journal of Cancer</i> , 2018, 143, 2299-2310.	2.3	46
131	Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. <i>Vaccine</i> , 2018, 36, 3820-3829.	1.7	33
132	Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection. <i>Journal of Infectious Diseases</i> , 2018, 218, 927-936.	1.9	5
133	Extension of the viral ecology in humans using viral profile hidden Markov models. <i>PLoS ONE</i> , 2018, 13, e0190938.	1.1	23
134	Cohort Profile: The Janus Serum Bank Cohort in Norway. <i>International Journal of Epidemiology</i> , 2017, 46, dyw027.	0.9	55
135	Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60. <i>BMJ Open</i> , 2017, 7, e014788.	0.8	23
136	Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population. <i>International Journal of Cancer</i> , 2017, 141, 200-209.	2.3	12
137	Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. <i>Journal of Clinical Virology</i> , 2017, 90, 64-69.	1.6	3
138	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	1.9	20
139	Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. <i>Journal of Infectious Diseases</i> , 2017, 216, 966-968.	1.9	8
140	Viruses in cancers among the immunosuppressed. <i>International Journal of Cancer</i> , 2017, 141, 2498-2504.	2.3	20
141	Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. <i>BMJ Open</i> , 2017, 7, e015867.	0.8	67
142	Cancer Registry follow-up for 17.5 million person-years of a nationwide maternity cohort. <i>Cancer Medicine</i> , 2017, 6, 3060-3064.	1.3	20
143	Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 264.e1-264.e7.	0.7	37
144	Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: A nationwide cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 48.e1-48.e15.	0.7	19

#	ARTICLE	IF	CITATIONS
145	Cancer risks after solid organ transplantation and after long-term dialysis. <i>International Journal of Cancer</i> , 2017, 140, 1091-1101.	2.3	66
146	Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. <i>BMJ Open</i> , 2017, 7, e017070.	0.8	22
147	Viruses in case series of tumors: Consistent presence in different cancers in the same subject. <i>PLoS ONE</i> , 2017, 12, e0172308.	1.1	6
148	Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. <i>PLoS Medicine</i> , 2017, 14, e1002414.	3.9	37
149	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. <i>PLoS ONE</i> , 2016, 11, e0147029.	1.1	102
150	Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. <i>Journal of Clinical Virology</i> , 2016, 80, 36-39.	1.6	26
151	Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 839-845.	0.8	5
152	Registry-based assessment of the status of cervical screening in Sweden. <i>Journal of Medical Screening</i> , 2016, 23, 217-226.	1.1	24
153	Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. <i>Journal of Clinical Virology</i> , 2016, 78, 89-92.	1.6	5
154	Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. <i>BMJ</i> , The, 2016, 352, i276.	3.0	40
155	Detection of DNA viruses in prostate cancer. <i>Scientific Reports</i> , 2016, 6, 25235.	1.6	28
156	Viremia during pregnancy and risk of childhood leukemia and lymphomas in the offspring: Nested case-control study. <i>International Journal of Cancer</i> , 2016, 138, 2212-2220.	2.3	15
157	Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden. <i>Cancer Research</i> , 2016, 76, 643-651.	0.4	23
158	Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 721-724.	1.1	17
159	Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. <i>Vaccine</i> , 2016, 34, 1559-1565.	1.7	42
160	Laboratory audit as part of the quality assessment of a primary HPV-screening program. <i>Journal of Clinical Virology</i> , 2016, 75, 33-36.	1.6	17
161	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. <i>Journal of Infectious Diseases</i> , 2016, 213, 199-205.	1.9	56
162	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	12.5	154

#	ARTICLE	IF	CITATIONS
163	Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. PLoS ONE, 2016, 11, e0156215.	1.1	5
164	Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial. International Journal of Cancer, 2015, 136, 350-359.	2.3	13
165	The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134185.	1.1	36
166	Molecular methods for identification and characterization of novel papillomaviruses. Clinical Microbiology and Infection, 2015, 21, 808-816.	2.8	56
167	Prevention of Human Papillomavirus-Associated Cancers. Seminars in Oncology, 2015, 42, 272-283.	0.8	18
168	Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally. Journal of the National Cancer Institute, 2015, 107, 1-5.	3.0	34
169	Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: A 14-year follow-up of a randomized primary HPV screening trial. International Journal of Cancer, 2015, 136, 1171-1180.	2.3	48
170	International standardization and classification of human papillomavirus types. Virology, 2015, 476, 341-344.	1.1	213
171	Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. Journal of Clinical Virology, 2015, 64, 88-91.	1.6	6
172	Organization and quality of HPV vaccination programs in Europe. Vaccine, 2015, 33, 1673-1681.	1.7	28
173	Near full control of human papillomavirus vaccine types. Lancet Infectious Diseases, The, 2015, 15, 1251-1252.	4.6	0
174	Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Vaccine Journal, 2015, 22, 943-948.	3.2	78
175	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 22-31.	4.5	181
176	Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	33
177	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
178	Cervical cancer screening in Europe: Quality assurance and organisation of programmes. European Journal of Cancer, 2015, 51, 950-968.	1.3	127
179	Does human papillomavirus-negative condylomata exist?. Virology, 2015, 485, 283-288.	1.1	36
180	Fewer than three doses of HPV vaccine. Lancet Oncology, The, 2015, 16, e422-e423.	5.1	0

#	ARTICLE	IF	CITATIONS
181	European Code against Cancer 4th Edition: Infections and Cancer. <i>Cancer Epidemiology</i> , 2015, 39, S120-S138.	0.8	34
182	Human papillomavirus type 197 is commonly present in skin tumors. <i>International Journal of Cancer</i> , 2015, 136, 2546-2555.	2.3	50
183	A basis for translational cancer research on aetiology, pathogenesis and prognosis: Guideline for standardised and population-based linkages of biobanks to cancer registries. <i>European Journal of Cancer</i> , 2015, 51, 1018-1027.	1.3	8
184	Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. <i>PLoS ONE</i> , 2015, 10, e0127444.	1.1	7
185	Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance. <i>PLoS ONE</i> , 2014, 9, e88323.	1.1	38
186	Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia. <i>PLoS ONE</i> , 2014, 9, e99114.	1.1	75
187	Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. <i>Journal of Clinical Microbiology</i> , 2014, 52, 449-459.	1.8	72
188	A Complex Intervention for Workflow Enhancement at the Swedish Cervical Cytology Biobank. <i>Biopreservation and Biobanking</i> , 2014, 12, 69-73.	0.5	12
189	Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 597.	3.8	80
190	Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2757-2764.	1.1	51
191	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. <i>Infectious Agents and Cancer</i> , 2014, 9, 4.	1.2	14
192	Metagenomic sequencing of expressed prostate secretions. <i>Journal of Medical Virology</i> , 2014, 86, 2042-2048.	2.5	12
193	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532.	6.3	1,282
194	Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 844-848.	2.3	17
195	Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. <i>BMJ, The</i> , 2014, 348, g130-g130.	3.0	103
196	Are 20 human papillomavirus types causing cervical cancer?. <i>Journal of Pathology</i> , 2014, 234, 431-435.	2.1	190
197	Deep sequencing extends the diversity of human papillomaviruses in human skin. <i>Scientific Reports</i> , 2014, 4, 5807.	1.6	95
198	Merkel Cell Polyomavirus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 357-367.		0

#	ARTICLE	IF	CITATIONS
199	A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. <i>Virology</i> , 2013, 445, 224-231.	1.1	243
200	Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation. <i>Journal of General Virology</i> , 2013, 94, 1841-1849.	1.3	4
201	Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. <i>Journal of Clinical Virology</i> , 2013, 56, 336-341.	1.6	25
202	Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. <i>Journal of General Virology</i> , 2013, 94, 1096-1103.	1.3	9
203	Next generation sequencing for human papillomavirus genotyping. <i>Journal of Clinical Virology</i> , 2013, 58, 437-442.	1.6	46
204	Diversity of human papillomaviruses in skin lesions. <i>Virology</i> , 2013, 447, 300-311.	1.1	32
205	The Swedish Cervical Cytology Biobank: Sample Handling and Storage Process. <i>Biopreservation and Biobanking</i> , 2013, 11, 19-24.	0.5	26
206	Prospective Study of HPV16 Viral Load and Risk of <i>In Situ</i> and Invasive Squamous Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 150-158.	1.1	38
207	Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program. <i>Vaccine</i> , 2013, 31, 4935-4939.	1.7	14
208	Metagenomic sequencing of HPV-negative condylomas detects novel putative HPV types. <i>Virology</i> , 2013, 440, 1-7.	1.1	66
209	Clinical trials of human papillomavirus vaccines and beyond. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 400-410.	12.5	147
210	Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 469-474.	3.0	123
211	High-Throughput Monitoring of Human Papillomavirus Type Distribution. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 242-250.	1.1	29
212	Primary human papillomavirus testing in organized cervical screening. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 11-16.	0.9	37
213	Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination. <i>American Journal of Epidemiology</i> , 2013, 178, 625-634.	1.6	87
214	Prospective study of genital human papillomaviruses and nonmelanoma skin cancer. <i>International Journal of Cancer</i> , 2013, 133, 1840-1845.	2.3	23
215	Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2706-2713.	0.3	77
216	O16.6...Pre-Vaccination Seroprevalence of 15 Human Papillomavirus (HPV) Types Among Slovenian Women Screened For Cervical Cancer. <i>Sexually Transmitted Infections</i> , 2013, 89, A58.2-A58.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Human Papillomavirus Typing in Reporting of Condyloma. Sexually Transmitted Diseases, 2013, 40, 123-129.	0.8	61
218	Unbiased Approach for Virus Detection in Skin Lesions. PLoS ONE, 2013, 8, e65953.	1.1	55
219	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. PLoS ONE, 2013, 8, e81171.	1.1	21
220	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. Vaccine Journal, 2012, 19, 449-451.	3.2	17
221	The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology. Journal of Clinical Microbiology, 2012, 50, 2289-2298.	1.8	63
222	Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer. American Journal of Epidemiology, 2012, 175, 685-695.	1.6	50
223	Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ: British Medical Journal, 2012, 344, e670-e670.	2.4	79
224	Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2012, 50, 1539-1544.	1.8	25
225	Screening and cervical cancer cure: population based cohort study. BMJ: British Medical Journal, 2012, 344, e900-e900.	2.4	153
226	International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine, 2012, 30, 294-299.	1.7	22
227	Phylogenetically diverse TT virus viremia among pregnant women. Virology, 2012, 432, 427-434.	1.1	26
228	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. Vaccine, 2012, 30, F100-F106.	1.7	91
229	Randomised health services studies. International Journal of Cancer, 2012, 131, 2898-2902.	2.3	36
230	Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. Journal of General Virology, 2011, 92, 1769-1777.	1.3	22
231	Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. British Journal of Cancer, 2011, 104, 178-180.	2.9	30
232	Genotyping of human papillomavirus in triaging of low-grade cervical cytology. American Journal of Obstetrics and Gynecology, 2011, 205, 145.e1-145.e6.	0.7	17
233	Randomized healthservices study of human papillomavirus based management of low grade cytological abnormalities. International Journal of Cancer, 2011, 129, 151-159.	2.3	15
234	High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. International Journal of Cancer, 2011, 129, 2643-2650.	2.3	72

#	ARTICLE	IF	CITATIONS
235	Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2541-2550.	1.1	77
236	Antibodies to Merkel Cell Polyomavirus Correlate to Presence of Viral DNA in the Skin. <i>Journal of Infectious Diseases</i> , 2011, 203, 1096-1100.	1.9	42
237	Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: case-control study. <i>Journal of General Virology</i> , 2011, 92, 2784-2791.	1.3	36
238	Cervical Cytology Biobanks as a Resource for Molecular Epidemiology. <i>Methods in Molecular Biology</i> , 2011, 675, 279-298.	0.4	27
239	Biobanks Collected for Routine Healthcare Purposes: Build-Up and Use for Epidemiologic Research. <i>Methods in Molecular Biology</i> , 2011, 675, 113-125.	0.4	12
240	Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples. <i>Virology</i> , 2010, 397, 331-336.	1.1	38
241	Prospective study of human papillomavirus and risk of cervical adenocarcinoma. <i>International Journal of Cancer</i> , 2010, 127, 1923-1930.	2.3	54
242	Cervical Cytology Biobanking in Europe. <i>International Journal of Biological Markers</i> , 2010, 25, 117-125.	0.7	21
243	Global Proficiency Study of Human Papillomavirus Genotyping. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4147-4155.	1.8	104
244	Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. <i>Journal of General Virology</i> , 2010, 91, 1840-1848.	1.3	29
245	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. <i>Journal of the National Cancer Institute</i> , 2010, 102, 325-339.	3.0	493
246	Ensuring quality in studies linking cancer registries and biobanks. <i>Acta Oncologica</i> , 2010, 49, 368-377.	0.8	19
247	Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2469-2478.	1.1	56
248	Monitoring of human papillomavirus vaccination. <i>Clinical and Experimental Immunology</i> , 2010, 163, 17-25.	1.1	46
249	<i>Staphylococcus aureus</i> and Squamous Cell Carcinoma of the Skin. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 472-478.	1.1	65
250	Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2009, 47, 541-546.	1.8	130
251	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 926-935.	1.9	528
252	No Risk of Maternal EBV Infection for Childhood Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2790-2792.	1.1	14

#	ARTICLE	IF	CITATIONS
253	Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2009, 101, 88-99.	3.0	249
254	Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. <i>Hum Vaccin</i> , 2009, 5, 696-704.	2.4	184
255	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. <i>Journal of Infectious Diseases</i> , 2009, 199, 936-944.	1.9	243
256	Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 188.e1-188.e7.	0.7	8
257	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. <i>International Journal of Cancer</i> , 2009, 124, 516-520.	2.3	557
258	The Bcl-2 inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma. <i>International Journal of Cancer</i> , 2009, 124, 2361-2366.	2.3	27
259	Editorial. <i>International Journal of Cancer</i> , 2009, 125, vii-vii.	2.3	2
260	Cutaneous human papillomavirus 88: Remarkable differences in viral load. <i>International Journal of Cancer</i> , 2008, 122, 477-480.	2.3	13
261	Screening-Preventable Cervical Cancer Risks: Evidence From a Nationwide Audit in Sweden. <i>Journal of the National Cancer Institute</i> , 2008, 100, 622-629.	3.0	307
262	Differences in transcriptional activity of cutaneous human papillomaviruses. <i>Virus Research</i> , 2008, 137, 213-219.	1.1	4
263	High-Throughput Genotyping of Oncogenic Human Papilloma Viruses with MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2008, 54, 86-92.	1.5	50
264	Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. <i>BMJ: British Medical Journal</i> , 2008, 337, a1754-a1754.	2.4	525
265	Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 189-195.	1.1	76
266	Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. <i>Journal of General Virology</i> , 2008, 89, 2467-2474.	1.3	47
267	In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses. <i>Journal of Virology</i> , 2007, 81, 9346-9356.	1.5	54
268	HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study. <i>British Journal of Cancer</i> , 2007, 97, 129-132.	2.9	72
269	Nordic biological specimen banks as basis for studies of cancer causes and control - more than 2 million sample donors, 25 million person years and 100 000 prospective cancers. <i>Acta Oncologica</i> , 2007, 46, 286-307.	0.8	85
270	Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. <i>Journal of General Virology</i> , 2007, 88, 814-822.	1.3	58

#	ARTICLE	IF	CITATIONS
271	Cutaneous Human Papillomaviruses Found in Sun-Exposed Skin: <i>Beta</i> Papillomavirus Species 2 Predominates in Squamous Cell Carcinoma. <i>Journal of Infectious Diseases</i> , 2007, 196, 876-883.	1.9	162
272	Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. <i>Journal of General Virology</i> , 2007, 88, 792-802.	1.3	28
273	Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1589-1597.	13.9	701
274	Population-based study of screening test performance indices of three human papillomavirus DNA tests. <i>Journal of Medical Virology</i> , 2007, 79, 1169-1175.	2.5	24
275	Translational Mini-Review Series on Vaccines: Monitoring of human papillomavirus vaccination. <i>Clinical and Experimental Immunology</i> , 2007, 148, 199-207.	1.1	47
276	Characterization of two novel cutaneous human papillomaviruses, HPV93 and HPV96. <i>Journal of General Virology</i> , 2007, 88, 1479-1483.	1.3	27
277	Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. <i>Vaccine</i> , 2006, 24, S233-S241.	1.7	52
278	Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays – an update. <i>Vaccine</i> , 2006, 24, S193-S200.	1.7	35
279	Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. <i>International Journal of Cancer</i> , 2006, 118, 1508-1514.	2.3	47
280	Subtype HPV38b[FA125] demonstrates heterogeneity of human papillomavirus type 38. <i>International Journal of Cancer</i> , 2006, 119, 1073-1077.	2.3	33
281	Activation of Maternal Epstein-Barr Virus Infection and Risk of Acute Leukemia in the Offspring. <i>American Journal of Epidemiology</i> , 2006, 165, 134-137.	1.6	31
282	Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 650-657.	0.7	56
283	Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. <i>Journal of General Virology</i> , 2005, 86, 1703-1708.	1.3	35
284	Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. <i>Journal of General Virology</i> , 2005, 86, 65-73.	1.3	12
285	Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?. <i>Expert Reviews in Molecular Medicine</i> , 2004, 6, 1-21.	1.6	6
286	High Prevalence of Cutaneous Human Papillomavirus DNA on the Top of Skin Tumors but not in Stripped Biopsies from the Same Tumors. <i>Journal of Investigative Dermatology</i> , 2004, 123, 388-394.	0.3	129
287	Human papillomavirus genotypes in cervical cancers in Mozambique. <i>Journal of General Virology</i> , 2004, 85, 2189-2190.	1.3	30
288	Maternal Herpesvirus Infections and Risk of Acute Lymphoblastic Leukemia in the Offspring. <i>American Journal of Epidemiology</i> , 2003, 158, 207-213.	1.6	78

#	ARTICLE	IF	CITATIONS
289	Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. <i>Journal of General Virology</i> , 2003, 84, 2105-2109.	1.3	83
290	Seroepidemiology of the human polyomaviruses. <i>Journal of General Virology</i> , 2003, 84, 1499-1504.	1.3	268
291	Preventive human papillomavirus vaccination. <i>Sexually Transmitted Infections</i> , 2002, 78, 4-6.	0.8	17
292	Evaluation of cost-effective precision ratios of different strategies for ELISA measurement of serum antibody levels. <i>Journal of Immunological Methods</i> , 2002, 271, 1-15.	0.6	28
293	Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish Women. <i>Journal of Medical Virology</i> , 2002, 66, 535-541.	2.5	63
294	Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2001, 344, 1125-1131.	13.9	800
295	Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine. <i>Journal of the National Cancer Institute</i> , 2001, 93, 284-292.	3.0	540
296	Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. <i>Journal of Medical Microbiology</i> , 2001, 50, 468-471.	0.7	14
297	<i>Chlamydia trachomatis</i> infection as a risk factor for invasive cervical cancer. <i>International Journal of Cancer</i> , 2000, 85, 35-39.	2.3	254
298	Seroepidemiology of human papillomavirus type 73: A sexually transmitted low-risk virus. <i>International Journal of Cancer</i> , 2000, 85, 353-357.	2.3	14
299	Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. <i>International Journal of Cancer</i> , 2000, 87, 232-235.	2.3	34
300	Etiology of Squamous Cell Carcinoma of the Penis. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 189-193.	1.4	242
301	Cervical cancer screening in Sweden. <i>European Journal of Cancer</i> , 2000, 36, 2255-2259.	1.3	49
302	Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. , 2000, 87, 232.		1
303	Epidemiology of human papillomavirus infection. <i>Scandinavian Journal of Urology and Nephrology, Supplement</i> , 2000, , 194-200.	0.0	9
304	Human Serum Antibodies to a Major Defined Epitope of Human Herpesvirus 8 Small Viral Capsid Antigen. <i>Journal of Infectious Diseases</i> , 1999, 179, 1016-1020.	1.9	21
305	Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison [published erratum appears in <i>J Clin Pathol</i> 1999 Oct;52(10):790]. <i>Journal of Clinical Pathology</i> , 1999, 52, 498-503.	1.0	73
306	The serological response to papillomaviruses. <i>Seminars in Cancer Biology</i> , 1999, 9, 423-430.	4.3	193

#	ARTICLE	IF	CITATIONS
307	A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. , 1999, 80, 489-493.		59
308	High risk genital papillomavirus infections are not spread vertically. , 1999, 9, 23-29.		39
309	Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical Cancer. New England Journal of Medicine, 1999, 341, 1633-1638.	13.9	450
310	High risk genital papillomavirus infections are not spread vertically. , 1999, 9, 23.		1
311	Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study.. Journal of General Virology, 1999, 80, 391-398.	1.3	77
312	Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II&III. Apmis, 1998, 106, 417-424.	0.9	22
313	Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. , 1998, 75, 564-567.		97
314	Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969&1989. , 1998, 76, 341-344.		34
315	Stability over Time of Serum Antibody Levels to Human Papillomavirus Type 16. Journal of Infectious Diseases, 1998, 177, 1710-1714.	1.9	113
316	Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute, 1997, 89, 1293-1299.	3.0	118
317	Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas. Apmis, 1997, 105, 884-888.	0.9	12
318	Human papillomavirus antibody responses among patients with incident cervical carcinoma. Journal of Medical Virology, 1997, 52, 436-440.	2.5	22
319	Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ: British Medical Journal, 1997, 315, 646-649.	2.4	65
320	A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. , 1996, 68, 54-59.		57
321	A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. , 1996, 68, 415-419.		20
322	Seropositivities to Human Papillomavirus Types 16, 18, or 33 Capsids and to Chlamydia trachomatis Are Markers of Sexual Behavior. Journal of Infectious Diseases, 1996, 173, 1394-1398.	1.9	153
323	Different HLA-DR-DO haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. , 1996, 68, 409.		7
324	Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. Journal of Clinical Microbiology, 1996, 34, 3056-3062.	1.8	46

#	ARTICLE	IF	CITATIONS
325	Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. <i>BMJ: British Medical Journal</i> , 1996, 312, 537-539.	2.4	133
326	Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. <i>International Journal of Cancer</i> , 1995, 60, 377-382.	2.3	71
327	Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. <i>BMJ: British Medical Journal</i> , 1995, 311, 1346-1346.	2.4	78
328	A pilot study of risk-stratified cervical cancer screening. <i>Open Research Europe</i> , 0, 1, 84.	2.0	0
329	Shared Environment and Colorectal Cancer: A Nordic Pedigree Registry-based Cohort Study. <i>International Journal of Cancer</i> , 0, , .	2.3	1